Company Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Michael S. Richman MSBA |
Contact Details
Address: 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 United States | |
| Phone | 240-399-4900 |
| Website | nextcure.com |
Stock Details
| Ticker Symbol | NXTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001661059 |
| CUSIP Number | 65343E108 |
| ISIN Number | US65343E1082 |
| Employer ID | 47-5231247 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael S. Richman MSBA | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer |
| Dr. Han Myint FACP, M.D. | Chief Medical Officer |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Steven P. Cobourn CPA | Chief Financial Officer |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Kevin G. Shaw | General Counsel |
| Stacy Rollinger | Vice President of Human Resources |
| Sourav Kundu Ph.D. | Senior Vice President of Development and Manufacturing |
| Dr. Sebastien Maloveste | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 14, 2023 | 8-K | Current Report |
| Nov 2, 2023 | 10-Q | Quarterly Report |